

265 Watline Avenue, Mississauga, Ontario L4Z 1P3  
Tel: 905-361-8910 Fax: 905-361-8911

# Microbix Presenting Product Results at Industry Conference

# Two Abstracts on IVD Controls at EMMD, October 9-11, 2019

**MISSISSAUGA, October 8, 2019** - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces it is making two presentations about the performance of its in-vitro diagnostics quality products (IVD Controls) at the 11th European Meeting on Molecular Diagnostics (EMMD) in Noordwijk, The Netherlands, October 9-11, 2019.

The first is titled “Novel high-risk (hr) HPV NAAT Positive Controls for cross-platform quality control.” It reviews the performance of Microbix’s novel CE-Marked and FDA-registered medical devices that support quality control of nucleic acid amplification tests (NAATs) for high-risk types of Human Papilloma Virus (HPV). The results show Microbix’s IVD Controls for HPV tests contain all required diagnostic targets, support all test steps, and are compatible with the leading NAAT instrument platforms.

The second is titled “Emerging requirements for infectious disease IVD quality control material.” It assesses the use of Microbix’s liquid-stable External Quality Assessment (EQA) samples for respiratory viruses (Microbix’s EQA Respiratory Virus Panel) to support the quality objectives of clinical laboratory testing. The results establish that Microbix’s innovative EQA Respiratory Virus Panel works across 19 leading diagnostics company testing platforms – in both the immunologic assay and NAAT categories.

Microbix believes these results show it is addressing the need for effective controls to support the quality objectives of clinical labs testing for high-risk HPV infections or respiratory infections across many diagnostic instrument platforms. It also believes that these products will assist with the provision of effective healthcare globally and that they represent meaningful new revenue opportunities for Microbix.

Two scientific “posters” authored by Microbix’s development teams provide the respective product performance results in a complete and succinct fashion, and are being presented by its Director of Quality Assessment Products (QAPs™), Pavel Zhelev, and its Director of R&D, Amer Alagic. The full posters will be made available on the company website, www.microbix.com, after their presentation at EMMD and include Microbix’s thankful acknowledgement of its collaborators.

# About Microbix Biosystems Inc.

Microbix specializes in developing proprietary biological and technology solutions for human health and well-being, with sales now exceeding $1 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical laboratory proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests as fully-regulated medical devices. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations.

Microbix also applies its biological expertise and infrastructure to create other proprietary new products and technologies. Currently it is has two; (1) Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots and (2) LumiSort™ cell-sorting, a technology platform for ultra-rapid and efficient sorting of cells or other particles.

Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.

# About EMMD

The European Meeting on Molecular Diagnostics (EMMD) is devoted to all aspects of molecular diagnostics in human disease and pathology. The EMMD is organized every two years in the Netherlands. These meetings are a continuation of the former Benelux and European meetings on Polymerase Chain Reaction (PCR) diagnostics. However the scope of the meeting has expanded to include other amplification techniques, general probe technologies, and applications across a wide diversity of laboratory disciplines (i.e., Clinical Microbiology, Virology, Pathology, Clinical Chemistry, Clinical Genetics, Pharmacogenetics, Hematology, and Oncology).

# Forward-Looking Information

This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of EMMD and the presented abstracts, the content, meaning or consequences of the abstracts, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.

Please visit www.microbix.com or www.sedar.com for recent Microbix news and filings.

For further information, please contact Microbix at:

|  |  |  |
| --- | --- | --- |
| Cameron Groome, CEO  (905) 361-8910 | Jim Currie, CFO  (905) 361-8910 | Deborah Honig, Investor Relations  Adelaide Capital Markets  (647) 203-8793 ir@microbix.com |

*Copyright © 2019 Microbix Biosystems Inc. Microbix®, Kinlytic®, LumiSort™ and QAPs™ are trademarks of the Company*